Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A. Switzer, David C. Hess, Adviye Ergul, Jennifer L. Waller, Livia S. MacHado, Vera Portik-Dobos, L. Creed Pettigrew, Wayne M. Clark, Susan C. Fagan

Research output: Contribution to journalArticle

72 Scopus citations

Abstract

Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

Original languageEnglish (US)
Pages (from-to)2633-2635
Number of pages3
JournalStroke
Volume42
Issue number9
DOIs
StatePublished - Sep 1 2011

    Fingerprint

Keywords

  • acute stroke
  • inflammation
  • neuroprotection

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Switzer, J. A., Hess, D. C., Ergul, A., Waller, J. L., MacHado, L. S., Portik-Dobos, V., Pettigrew, L. C., Clark, W. M., & Fagan, S. C. (2011). Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke, 42(9), 2633-2635. https://doi.org/10.1161/STROKEAHA.111.618215